Dipyridamole with aspirin for secondary stroke prevention

Lancet

Volumn 367, Issue 9523, 2006, Pages 1638-1639

  Norrving, Bo ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; DIPYRIDAMOLE;

ABSENCE OF SIDE EFFECTS; ANGINA PECTORIS; ARTICLE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG ACTIVITY; DRUG EFFECT; HEADACHE; HEART DISEASE; HEART INFARCTION; HUMAN; LIFESTYLE; META ANALYSIS; PRIORITY JOURNAL; RISK FACTOR; SYSTEMATIC REVIEW; TRANSIENT ISCHEMIC ATTACK;

EID: 33646575927     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(06)68711-4     Document Type: Note

References (13)

1. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction and stroke in high risk patients. BMJ 324 (2000) 71-86
2. De Schryver E., Algra A., and van Gijn J. Dipyridamole for preventing stroke and other vascular events in patients with vascular disease. Cochrane Database Syst Rev 2 (2006) CD001820
3. CAPRIE Steering Committee. A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet 348 (1996) 1329-1339
4. ESPRIT Study Group. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet 367 (2006) 1665-1673
5. Diener H., Bogousslavsky J., Brass L., and on behalf of the MATCH investigators. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 364 (2004) 331-337
6. Bhatt D., Fox K., Hacke W., and on behalf of the CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 354 (2006) 1706-1717
7. Diener H., Cunha L., Forbes C., Sivenius J., Smets P., and Lowenthal A. European Stroke Prevention Study 2: dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 143 (1996) 1-13
8. Donnan G., and Davis S. Aspirin therapy should be first line: probably, but watch this space. Stroke 33 (2002) 2139-2140
9. Leonardi-Bee J., Bath P., Bousser M.-G., and on behalf of the Dipyridamole in Stroke Collaboration (DISC). Dipyridamole for preventing recurrent ischemic stroke and other vascular events: a meta-analysis of individual patient data from randomized controlled trials. Stroke 36 (2005) 162-168
10. De Schryver E., and for the ESPRIT Study Group. Dipyridamole in stroke prevention: effect of dipyridamole on blood pressure. Stroke 34 (2003) 2339-2342
11. Weyrich A., Denis M., Kuhlmann-Eyre J., et al. Dipyridamole selectively inhibits inflammatory gene expression in platelet-monocyte aggregates. Circulation 111 (2005) 633-642
12. Jones L., Griffin S., Palmer S., et al. Clinical effectiveness and cost-effectiveness of clopidogrel andmodified-release dipyridamole in the secondary prevention of occlusive vascular events: a systematic review and economic evaluation. Health Technol Assess 8 (2004) 1-196
13. Bhatt D., Steg P., Ohman E., and for the REACH Registry Investigators. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 295 (2006) 180-189